2 weeks Ago By ABMN Staff
American Century Companies Inc. grew its position in shares of Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ) by 16.4% during the second quarter, Holdings Channel reports.
The institutional investor owned 29,167 shares of the biotechnology company’s stock after purchasing an additional 4,104 shares during the quarter. American Century Companies Inc.’s holdings in Ligand Pharmaceuticals were worth $2,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in LGND. Vanguard Group Inc. lifted its holdings in Ligand Pharmaceuticals by 0.
4% during the first quarter. Vanguard Group Inc. now owns 1,884,112 shares of the biotechnology company’s stock valued at $137,729,000 after purchasing an additional 7,598 shares during the last quarter.
Stephens Investment Management Group LLC lifted its stake in shares of Ligand Pharmaceuticals by 41.0% during the 4th quarter. Stephens Investment Management Group LLC now owns 659,434 shares of the biotechnology company’s stock valued at $47,097,000 after buying an additional 191,870 shares in the last quarter.
Chicago Capital LLC boosted its holdings in Ligand Pharmaceuticals by 124.3% in the 2nd quarter. Chicago Capital LLC now owns 514,946 shares of the biotechnology company’s stock worth $43,389,000 after buying an additional 285,350 shares during the period.
Rice Hall James & Associates LLC grew its stake in Ligand Pharmaceuticals by 4.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 292,475 shares of the biotechnology company’s stock valued at $24,644,000 after buying an additional 12,691 shares in the last quarter.
Finally, Ashford Capital Management Inc. purchased a new position in Ligand Pharmaceuticals in the 1st quarter valued at approximately $14,367,000. Institutional investors own 91.
28% of the company’s stock. Wall Street Analysts Forecast Growth Several research firms have issued reports on LGND. HC Wainwright restated a “buy” rating and set a $144.
00 target price on shares of Ligand Pharmaceuticals in a research report on Thursday, August 8th. Craig Hallum raised their target price on Ligand Pharmaceuticals from $135.00 to $140.
00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $130.00 target price on shares of Ligand Pharmaceuticals in a report on Wednesday, August 7th.
Finally, Benchmark increased their price target on shares of Ligand Pharmaceuticals from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, August 12th.
One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Ligand Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $131.
00. Insider Activity at Ligand Pharmaceuticals In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $106.
39, for a total value of $159,585.00. Following the completion of the sale, the insider now owns 22,534 shares of the company’s stock, valued at $2,397,392.
26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link . In other news, COO Matthew E.
Korenberg sold 11,389 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $105.61, for a total value of $1,202,792.
29. Following the completion of the sale, the chief operating officer now owns 49,510 shares of the company’s stock, valued at approximately $5,228,751.10.
The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, insider Andrew Reardon sold 1,500 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $106.
39, for a total value of $159,585.00. Following the sale, the insider now owns 22,534 shares of the company’s stock, valued at $2,397,392.
26. The disclosure for this sale can be found here . Insiders have sold a total of 51,613 shares of company stock valued at $5,255,692 over the last 90 days.
5.90% of the stock is owned by insiders. Ligand Pharmaceuticals Stock Performance NASDAQ:LGND opened at $97.
37 on Friday. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 18.
83 and a beta of 1.01. The stock has a fifty day moving average of $102.
88 and a 200 day moving average of $88.31. Ligand Pharmaceuticals Incorporated has a 52-week low of $49.
24 and a 52-week high of $112.13. Ligand Pharmaceuticals ( NASDAQ:LGND – Get Free Report ) last released its quarterly earnings results on Tuesday, August 6th.
The biotechnology company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.
34. The business had revenue of $41.50 million during the quarter, compared to analysts’ expectations of $33.
04 million. Ligand Pharmaceuticals had a net margin of 29.69% and a return on equity of 7.
91%. The business’s quarterly revenue was up 57.2% compared to the same quarter last year.
During the same quarter in the previous year, the company earned $1.10 EPS. Equities analysts forecast that Ligand Pharmaceuticals Incorporated will post 3.
54 earnings per share for the current fiscal year. Ligand Pharmaceuticals Company Profile ( Free Report ) Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Featured Articles Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND – Free Report ). Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
